胆汁酸信号在MASLD中的作用:从发病机制到治疗应用
本综述总结胆汁酸信号在代谢功能障碍相关脂肪性肝病(MASLD)发病机制中的作用,以及胆汁酸受体激动剂和胆汁酸转运调节剂的实验与临床研究证据,并展望靶向胆汁酸信号治疗MASLD的未来机遇与挑战。
要点
- 胆汁酸受体调控肝脏代谢与肠道完整性,是MASLD病理生理的核心环节。
- 靶向肠-肝轴胆汁酸受体的激动剂或转运调节是当前临床研究热点。
- 综述汇总实验与临床研究证据,并指出未来治疗实施的机遇与挑战。
核心结论
- 胆汁酸信号通过调控肝脏代谢和肠道完整性参与MASLD发病,靶向胆汁酸受体是潜在治疗策略。
研究设计与样本
- 综述,总结胆汁酸信号在MASLD中的机制、胆汁酸受体激动剂的实验与临床研究证据,并展望未来。
主要发现
- 脂质和葡萄糖代谢失调促进肝细胞应激、炎症和肝纤维化,可进展为肝硬化和肝癌。
- 肠道菌群失调和细菌易位触发肝脏及全身炎症,促进MASLD发病和进展。
- 胆汁酸受体调控肝脏代谢和肠道完整性,是MASLD病理生理的核心参与者。
临床怎么用
- 靶向肠-肝轴胆汁酸受体的激动剂或胆汁酸转运调节策略目前处于临床研究阶段。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The increasing prevalence of metabolic dysfunction-associated steatotic liver disease (MASLD) causes considerable global morbidity and mortality. Dysregulated lipid and glucose metabolism are central elements in the pathogenesis of MASLD by promoting hepatocellular stress, inflammation, and liver fibrosis that may culminate in the development of cirrhosis and liver cancer. Moreover, intestinal dysbiosis and bacterial translocation trigger hepatic and systemic inflammation, further contributing to the pathogenesis and progression of MASLD. Bile acid (BA) receptors regulate hepatic metabolism and gut integrity as central players in the pathophysiology of MASLD. Therapeutic strategies targeting these BA receptors along the gut-liver axis, either directly through agonists or indirectly via modulation of BA transport, are currently within the focus of clinical research. This review summarizes mechanistic aspects of BA signaling in MASLD, key evidence of experimental and clinical studies on BA receptor agonists, and provides an outlook for future opportunities and challenges on the road to the implementation of novel therapies targeting BA receptors and BA signaling in MASLD.
引用
- Simbrunner B, Paternostro R, Reiberger T, et al. Bile acid signaling in MASLD: From pathogenesis to therapeutic applications. Hepatology. 2025. PMID: 40971685. doi:10.1097/HEP.0000000000001539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。